Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 61, Issue 3, 1999, Pages 183-188

  Kritz, H ^c   Oguogho, A ^a   Arakil Aghajanian, A ^a   Sinzinger, H ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ALKADIENE; AMLODIPINE; CALCIUM ANTAGONIST; DILTIAZEM; LOW DENSITY LIPOPROTEIN; NIFEDIPINE; SESAMODIL FUMARATE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTROPHORETIC MOBILITY; HUMAN; HUMAN EXPERIMENT; LIPID OXIDATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0032737040     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.1999.0088     Document Type: Article

References (38)

1. Goldstein J. L., Brown M. S. The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem. 46:1977;897-930.
2. Steinberg D. Lipoproteins and atherosclerosis. A look back and a look ahead. Arteriosclerosis. 3:1983;283-301.
3. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witzim J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 320:1989;915-924.
4. Schwartz C. J., Valente A. J., Sprague B. A., Kelley J. L., Nerem R. M. The pathogenesis of atherosclerosis: an over-view. Clin Cardiol. 14:1991;110-116.
5. Tyroler H. A. Lowering plasma cholesterol levels decreases risk of coronary heart an overview of clinical trials. Steinberg D., Olefsky J. M. Hypercholesterolemia and atherosclerosis. 1987;99-166 Churchill Livingstone, New York.
6. Ylä-Herttuala S., Palinski W., Rosenfeld M. E. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
7. Palinski W., Rosenfeld M. E., Ylä-Herttuala S. Low-density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 86:1989;1372-1376.
8. Rosenfeld M. R., Palinski W., Ylä-Herttuala S., Butler S., Witztum J. L. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from VD-IHL rabbits. Arteriosclerosis. 10:1989;336-349.
9. Salonen J. T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonon R. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. i:1992;883-887.
10. Parthasarathy S., Printz D. J., Boyd D., Joy L., Steinberg D. Macrophage oxidation of low-density lipoproteins generates a modified form recognized by the scavenger-receptor. Arteriosclerosis. 6:1986;505-510.
11. Henriksen T., Mahoney E. M., Steinberg D. Enhanced macrophage degradation of low-density lipoprotein previously incubated with endothelial cells: recognition by receptors for acetylated low-density lipoproteins. Proc Natl Acad Sci USA. 78:1981;6499-6503.
12. Lehr H. A., Hübner C., Nolte D., Finckh B., Beisiegel U., Kohlschutter A., Messmer K. Oxidatively modified human low-density lipoprotein stimulates leucocyte adherence to the microvascular endothelium in-vivo. Res Exp Med. 191:1991;85-90.
13. Cushing S. D., Berliner J. A., Valente A. J. Minimally modified low-density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 87:1990;134-138.
14. Galle J., Mulsch A., Busse R., Bassenge E. Effects of native and oxidized low-density lipoprotein on formation and inactivation of endothelium-derived relaxing factor. Arterioscl Thromb. 11:1991;198-203.
15. Tanner F. C., Noll G., Boulanger C. M., Loscher T. F. Oxidized low-density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger-receptor and endothelium-derived nitric oxide. Circulation. 83:1991;2012-2020.
16. Sachinidis A., Locher R., Mengden T., Vetter W. Low-density lipoprotein elevates intracellular calcium and pH in vascular smooth muscles and fibroblasts without mediation of LDL-receptor. Biochem Biophys Res Commun. 167:1990;353-359.
17. Godfraind T. Classification of calcium antagonists. Am J Cardiol. 59:1987;11-23.
18. Fleckenstein A., Frei M., Fleckenstein-Grun G. Antihypertensive and arterial anticalcinotic effects of calcium antagonists. Am J Cardiol. 57:1986;1-10.
19. Held P. H., Yusuf S., Furberg C. D. Calcium-channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J. 229:1989;1189-1192.
20. Kritz H., Underwood S. R., Sinzinger H. Imaging of atherosclerosis (Part I). Wr klin Wschr. 108:1996;98-97.
21. Kritz H., Underwood S. R., Sinzinger H. Imaging of atherosclerosis (Part II). Wr klin Wschr. 108:1996;123-132.
22. Jackson C. L., Bush R. C., Bowyer D. E. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis. 80:1989;17-26.
23. Sinzinger H., Fitscha P. Antiatherosclerotic actions of isradipine. J Cardiovasc Pharmacol. 19:1992;29-31.
24. Weiss K., Fitscha P., O'Grady J., Sinzinger H. Isradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production. Thromb Res. 54:1989;311-317.
25. Noguchi N., Gotoh N., Niki E. Dynamics of the oxidation of low-density lipoprotein induced by free radicals. Biochim Biophys Acta. 1168:1993;348-357.
26. Esterbauer H., Gebicki J., Publ H., Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med. 13:1992;341-390.
27. Wallin B., Rosengren B., Shertzer H. G., Camejo G. Lipoprotein oxidation and measurement of thiobarbituric acid reactive substances formation in a single microtiter plate: its use for evaluation of antioxidants. Anal Biochem. 208:1993;10-15.
28. Henry D., Bentley K. I. Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest. 68:1981;1366-1369.
29. 125I-LDL-entry in hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 17:1991;546-549.
30. Sugano O., Nakashima Y., Matsushima T. Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injection. Arteriosclerosis. 6:1986;237-241.
31. Oguogho A. Eicosanoids, calcium antagonists and ASA on LDL-oxidation. Sinzinger H., Peskar B. A., O'Grady J. Eicosanoids and Fatty Acids. 1996;Facultas, Vienna.
32. Lupo E., Locher R., Weisser B., Vetter W. In vitro antioxidant activity of calcium antagonists against LDL-oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun. 203:1994;1803-1808.
33. 2-like compounds are produced in-vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 87:1990;9383-9387.
34. 2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol. 42:1986;15-19.
35. 2-isoprostanes) in plasma and low-density lipoprotein exposed to oxidative stress in vitro. J Clin Invest. 93:1994;998-1004.
36. Morrow J. D., Roberts L. J. II. Quantification of non-cyclooxygenase derived prostanoids as a marker of oxidative stress. Free Rad Biol Med. 10:1991;195-200.
37. Parthasarathy S., Barnett J. Phospholipase A2 activity of low-density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc Natl Acad Sci USA. 87:1990;9741-9750.
38. Steinbrecher U. P., Pritchard P. H. Hydrolysis of phosphatidylcholine during LDL-oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res. 30:1989;305-315.